Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation. - Wikidata - wikimedia - TriplyDB

Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation.

Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation.

http://www.wikidata.org/entity/Q45205869

about

Optimal management of seizures associated with tuberous sclerosis complex: current and emerging options Updates of mTOR inhibitors Mesenchymal-epithelial interactions involving epiregulin in tuberous sclerosis complex hamartomas Ribosomal Protein S6 Phosphorylation in the Nervous System: From Regulation to Function Roles of mTOR Signaling in Brain Development Epilepsy related to developmental tumors and malformations of cortical development The molecular biology of WHO grade I astrocytomas Potential for treatment of severe autism in tuberous sclerosis complex Pathological and molecular advances in pediatric low-grade astrocytoma Giant cells: contradiction to two-hit model of tuber formation?Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF- D levels decrease The differential effects of prenatal and/or postnatal rapamycin on neurodevelopmental defects and cognition in a neuroglial mouse model of tuberous sclerosis complex.A circuitry and biochemical basis for tuberous sclerosis symptoms: from epilepsy to neurocognitive deficits Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model.Comparison of three rapamycin dosing schedules in A/J Tsc2+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors Identification of the miRNA-target gene regulatory network in intracranial aneurysm based on microarray expression data.The genomic landscape of tuberous sclerosis complex Evidence for population variation in TSC1 and TSC2 gene expression Biallelic TSC gene inactivation in tuberous sclerosis complex Lymphangioleiomyomatosis and TSC2-/- cells The complexes of mammalian target of rapamycin.Oral findings in 58 adults with tuberous sclerosis complex Analysis of TSC cortical tubers by deep sequencing of TSC1, TSC2 and KRAS demonstrates that small second-hit mutations in these genes are rare events.Phenotypic variations in NF1-associated low grade astrocytomas: possible role for increased mTOR activation in a subset.Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways.Oral everolimus treatment in a preterm infant with multifocal inoperable cardiac rhabdomyoma associated with tuberous sclerosis complex and a structural heart defect.Enhanced epidermal growth factor, hepatocyte growth factor, and vascular endothelial growth factor expression in tuberous sclerosis complex.The mTOR signaling pathway as a treatment target for intracranial neoplasms Monoallelic germline TSC1 mutations are permissive for T lymphocyte development and homeostasis in tuberous sclerosis complex individuals.Prolonging the survival of Tsc2 conditional knockout mice by glutamine supplementation.Postnatal neurogenesis generates heterotopias, olfactory micronodules and cortical infiltration following single-cell Tsc1 deletion.Molecular Docking studies of FKBP12-mTOR inhibitors using binding predictions Lhermitte-Duclos disease: a report of 31 cases with immunohistochemical analysis of the PTEN/AKT/mTOR pathway.Molecular pathogenesis of lymphangioleiomyomatosis: lessons learned from orphans Fetal brain lesions in tuberous sclerosis complex: TORC1 activation and inflammation Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma.Akt-dependent and -independent mechanisms of mTOR regulation in cancer Loss of Tsc2 in radial glia models the brain pathology of tuberous sclerosis complex in the mouse.The pathogenesis and imaging of the tuberous sclerosis complex.The methylation of the TSC2 promoter underlies the abnormal growth of TSC2 angiomyolipoma-derived smooth muscle cells

P2860

Q22305852-FF52FE2E-5D98-4AB3-BE0D-11F74F2F14CB Q24607170-03BEF328-36B1-49F0-96D6-0F7E0BEE9FF6 Q24656058-D18EBBBE-F3FE-46C6-ABC9-5741AF6A1FAE Q26770762-112C19C4-7CC2-4D2F-A907-44260A245F99 Q26786097-335B24A7-D8AF-4D00-8892-19E0B73F41F0 Q26829946-B22D20E4-CA97-41DE-B106-DBB96FA301BE Q27010414-0A81450C-02B6-4E6A-99A3-F32AFAA52732 Q27021739-4224616D-C03D-4DD1-80F3-47F49E388090 Q27026123-4935D9DA-40EC-4822-A14F-1E8D51E44436 Q28256696-44D26490-1D05-46B4-9B76-121C2209F147 Q28476810-641D9478-6386-4EDE-9FFC-1CFCA0B1150D Q30518266-6D4DA0D3-DD82-441B-93C4-3734E1A2088A Q30597707-19C9CF3C-B246-4183-A270-5F2D9612F928 Q33316872-1AB4C240-E67E-46D6-9333-B6BDB6B4B387 Q33711691-64B43901-0999-4E65-9D90-4C1842174811 Q33744043-88480C16-C64E-424D-BC59-F41E49AF2DFE Q33826893-9F6B3E45-0891-4839-A083-9C6AA213DF43 Q33827600-5BA794B7-3701-4895-8B56-97FA5F5E1FB1 Q33899858-44BB2121-661E-48D1-99C9-2DDA49C7AC56 Q33904951-5CA43B23-B0F5-4E39-B719-AF62C8A70806 Q34116818-C0FB8D47-0857-466B-8583-C4B373B86CB5 Q34162958-33A094AF-8054-4306-A749-ACCEF9EE7AAA Q34182980-8AB69BCD-8303-4E08-BF65-7466CAFF3937 Q34467227-78C57186-4A0F-4B52-8EBA-1B00683C69E1 Q34562010-F3E1B941-F4CD-4CE2-AD5D-C0A0DBE11272 Q34589342-6FC0E097-2E56-487B-94D4-5ED73392CD5E Q34755802-CD89FEBD-67F6-469F-851C-11788D908EC2 Q34886859-F77202F4-8EC1-4DE7-81AF-E79ACDAC1FB7 Q35122010-C7448FB2-A8AD-4592-961E-555F45494DFA Q35278772-EE6BD950-502C-4E8B-B477-9150FB9F9365 Q35688636-3EF67631-12E3-4F82-B3B7-D6705A72FAF9 Q35881144-EB771057-E0AA-44A6-9F3A-2BE8608578E2 Q36100341-3289FBF6-7EB9-4885-A5DB-E7AF2CA5E0F8 Q36330644-07C8D6FF-B480-4883-8FCC-9DA325B1EBC9 Q36457269-895138BC-F530-40A6-8B26-40B592DDA7C3 Q36659706-D9C24410-DB32-4166-BCE7-7C274DF85104 Q37114404-64333743-3638-4CEB-B66A-F79DA09525E2 Q37128350-201E6946-1786-48DE-A496-AFB5D12526CB Q37139373-83C1DF34-1062-4EBA-A596-A9DC7307DC49 Q37197352-8B754634-BC70-43AB-B878-CF25605FBDD2

P2860

Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation.

http://www.wikidata.org/entity/Q45205869

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh-hant

name

Pathogenesis of tuberous scler ...... TSC2 leads to mTOR activation.

@en

Pathogenesis of tuberous scler ...... TSC2 leads to mTOR activation.

@nl

type

label

Pathogenesis of tuberous scler ...... TSC2 leads to mTOR activation.

@en

Pathogenesis of tuberous scler ...... TSC2 leads to mTOR activation.

@nl

prefLabel

Pathogenesis of tuberous scler ...... TSC2 leads to mTOR activation.

@en

Pathogenesis of tuberous scler ...... TSC2 leads to mTOR activation.

@nl

P1433

Q45205869-03B1C47B-7CF7-4044-8780-AF40080A08CB

P1476

Q45205869-94780398-844A-44B9-9BDB-19B37228F54C

P2093

Q45205869-3B104537-3F50-4036-BDBC-8ECC01B7394D

Q45205869-8DD48AE8-D29E-4D88-998E-8F52B9437EEA

Q45205869-B8F2BD5F-76D9-4496-B1C7-6F1BC59F4971

Q45205869-C5C377D5-BDF3-4C95-A760-7B9EA040A6F5

Q45205869-D9681154-414A-4BDB-A72D-53C91500400C

Q45205869-E1917284-43E0-4EBB-8A41-BD0388D3BA1C

P2860

Q45205869-1219F724-D8F7-4BC1-B811-A23DE73C0ECC

Q45205869-1486B2C3-8D1E-4A97-BCEB-948DD3AEF56E

Q45205869-2166AFA4-D14C-4290-8AD5-A30891CAB2A5

Q45205869-294F59F2-A6B0-4A47-BDFA-42F5878B3DC1

Q45205869-3149E548-595D-4F20-99C6-550436057F14

Q45205869-3CD61872-A270-4E82-AE37-FB5E94030770

Q45205869-3E01C689-550B-411F-A1E3-F91DCB9CEE0C

Q45205869-4E5E3A8E-2BBD-4B57-ADEE-AD4F4885C053

Q45205869-51596713-610D-47DC-BEB0-B88E8BFB912C

Q45205869-5E3724E2-ADD9-466E-8E9F-20C3B8A7F667

P304

Q45205869-4B96629E-DCF7-4662-9067-106D2692E5E1

P31

Q45205869-7D7236A9-5842-440B-8142-8407BAD3E5FD

P356

Q45205869-1A2D727E-679D-4A77-A20E-A8161E1A31BC

P433

Q45205869-B7080E99-D590-46BB-9C56-DB3B4C14E573

P478

Q45205869-C82600CE-B5AE-4498-B389-69929BC3A0B9

P50

Q45205869-2D8DAF7A-6C51-4BB8-9371-410CDC8D7D50

Q45205869-F7C39969-1864-4CA0-93E8-8A93E0B1E64D

P577

Q45205869-38BABF62-DD3D-482B-8DFD-DD06DBD1D850

P5875

Q45205869-E2F13347-5F2C-4A13-B733-BC58B29612AA

P698

Q45205869-4FEF37E6-DEE3-4268-8125-1A854A7B3A05

P356

P1433

Journal of Neuropathology & Experimental Neurology

P1476

Pathogenesis of tuberous scler ...... TSC2 leads to mTOR activation

@en

P2093

David J Kwiatkowski

http://www.w3.org/2001/XMLSchema#string

Grajkowska Wieslawa

http://www.w3.org/2001/XMLSchema#string

Hongbing Zhang

http://www.w3.org/2001/XMLSchema#string

Jennifer A Chan

http://www.w3.org/2001/XMLSchema#string

Joanna Lewin-Kowalik

http://www.w3.org/2001/XMLSchema#string

Penelope S Roberts

http://www.w3.org/2001/XMLSchema#string

P2860

Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products

Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs

TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling

A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells

Phosphatidylinositol 3-kinase/Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin

Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34

Identification and characterization of the tuberous sclerosis gene on chromosome 16

Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM)

Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent

Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway

P304

1236-1242

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JNEN/63.12.1236

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

63

http://www.w3.org/2001/XMLSchema#string

P50

Sergiusz Jóźwiak

Katarzyna Kotulska

P577

2004-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8105732

http://www.w3.org/2001/XMLSchema#string

P698

15624760

http://www.w3.org/2001/XMLSchema#string